Background {#s0001}
==========

South Africa accounts for approximately 18% of global human immunodeficiency virus (HIV) infections with an estimated prevalence of 6.7 million HIV-infected people.^[@CIT0001]^ There are almost 1000 new HIV infections, the majority of which are heterosexually transmitted.^[@CIT0002]^ In an attempt to end the surge of HIV plaguing the African continent, the Joint United Nations Programme on HIV/AIDS (UNAIDS) has established an ambitious but achievable target to have 90% of all people tested for HIV and treated and virologically suppressed by 2020.^[@CIT0003]^ Providing antiretroviral treatment (ART) to all people living with HIV (PLHIV) irrespective of CD4 count can help prevent HIV-related illness, avert acquired immune deficiency syndrome (AIDS)-related deaths and prevent new HIV infections.^[@CIT0003]^ South Africa implemented the UNAIDS policy in September 2016.^[@CIT0004]^ This universal access to ART for PLHIV is likely to lead to an increase in the burden of chronic diseases in South Africa as people are living longer with HIV.^[@CIT0005]^

The 2014 study by Stanifer et al. has shown that chronic kidney disease (CKD) has been prevalent and is at an increase in sub-Saharan Africa, with 24% of HIV-infected patients having hypertension (HPT), 18.9% having diabetes and 10% having co-morbid CKD.^[@CIT0006]^ The use of long-term medication for chronic illnesses can pose a threat to the kidneys, and the use of ART is no exception.^[@CIT0007],[@CIT0008],[@CIT0009]^ Tenofovir disoproxil fumarate (TDF), a potentially nephrotoxic drug,^[@CIT0010],[@CIT0011]^ is widely used as first-line ART in South Africa, and screening for baseline renal dysfunction prior to TDF initiation is essential.^[@CIT0012]^ The South African ART guidelines recommend a serum creatinine and creatinine clearance at baseline (prior to ART initiation) and then at three months, six months and annually thereafter for patients on TDF.^[@CIT0013]^

Our systematic scoping review has demonstrated a research gap in ART nephrotoxicity, particularly with TDF, as well as the long-term outcomes of renal function for patients on ART in South Africa. This is of great concern because we do not know the burden of ART nephrotoxicity or morbidity that our population may experience. Further, with the current health infrastructure, access to nephrologists and dedicated renal services are limited to a few tertiary hospitals. In this study, we aim to determine the risk factors and co-morbidities associated with changes in renal function in HIV-infected adults in South Africa. We anticipate that the results of this study will pave the way for prospective studies regarding the morbidity and mortality of ART nephrotoxicity and influence the expansion of renal services offered in the public health sector.

Methodology {#s0002}
===========

Design {#s20003}
------

We conducted a retrospective study of 350 ART-naïve adult patients (18 years and older) attending the King Edward VIII HIV clinic, Durban, South Africa.

Study population {#s20004}
----------------

Our study population was ART-naïve, HIV-infected adult patients who presented to us from across KwaZulu-Natal seeking initiation on ART. We included patients who were initiated on ART from April 2010 to December 2013 and followed up over a 24-month period. Patients already on ART who were transferred to the clinic were excluded.

Data extraction {#s20005}
---------------

Clinical data were extracted from medical records of patients attending the HIV clinic at King Edward VIII Hospital in the study period from April 2010 to December 2013. Data were collected at baseline (pre-ART) and at six, 12, 18 and 24 months on ART. Data collected included socio-demographics, clinical parameters (weight, height, body mass index \[BMI\], blood pressure \[BP\], pulse, finger prick glucose and urine dipstick analysis), history of co-morbidities (HPT, diabetes, tuberculosis \[TB\] and pregnancy), laboratory data (serum creatinine and estimated glomerular filtration rate \[eGFR\]) and the type of ART regimen. We also documented patients who were lost to follow-up.

Outcome measures {#s20006}
----------------

Chronic kidney disease was defined as either kidney damage or a GFR \< 60 mL/min/1.73 m^2^ for ≥ three months irrespective of cause.^[@CIT0014]^ Estimated GFR (eGFR) used in data analyses was calculated using the simplified Modification of Diet in Renal Disease (MDRD) equation without the ethnicity factor: eGFR (mL/min/1.73 m^2^) = 175 × \[S~cr~(µmol/L)/88.4\]^−1.154^ × Age (years)^−0.203^ × (0.742, if female)^[@CIT0015]^ and was performed at the National Health Laboratory Services (NHLS) at King Edward VIII Hospital. The formula was adjusted to correct for the use of µmol/L as the unit of measure for serum creatinine.^[@CIT0015]^ For this study, we modified the staging of CKD from that of the Kidney Disease Outcomes Quality Initiative (KDOQI) of the National Kidney Foundation ([Table 1](#T0001){ref-type="table"})^[@CIT0014]^ because the NHLS reports creatinine clearance above 60 µmol/L as \> 60 µmol/L and does not specify the actual eGFR level. For those patients who did not have a documented eGFR from the lab because either the age or gender was not documented on the lab request form, we manually calculated the value using the MDRD equation above, with age and gender captured during data collection. Proteinuria detected on urine dipstick analysis refers to the presence of protein in the urine.

###### 

Staging of chronic kidney disease.

  Description[†](#TFN0001){ref-type="table-fn"}   eGFR mL/min/1.73 m^2^
  ----------------------------------------------- ------------------------
  Normal renal function                           ≥ 60
  Moderate renal impairment                       30--59
  Severe renal impairment                         15--29
  Kidney failure                                  \< 15 (needs dialysis)

eGFR, estimated glomerular filtration rate.

, An adaptation of the CKD classification of the KDOQI of National Kidney Foundation.

As per the South African Hypertension Guidelines, HPT is defined as a persistent elevation of BP ≥ 140/90 mmHg.^[@CIT0016]^ The classification of HPT into four categories was made in accordance with the JNC8 guidelines ([Table 2](#T0002){ref-type="table"}).^[@CIT0017]^ Body mass index (BMI) is an index of weight-for-height that is used to classify persons as underweight, normal, overweight or obese. Body mass index is calculated as weight (kilograms)/height (metres)². Classification of BMI was based on that of the World Health Organization (WHO) Global Database on BMI ([Table 3](#T0003){ref-type="table"}).^[@CIT0018]^

###### 

Classification of hypertension.

  Classification[†](#TFN0002){ref-type="table-fn"}   Systolic blood pressure (mmHg)[‡](#TFN0003){ref-type="table-fn"}   \-    Diastolic blood pressure (mmHg)
  -------------------------------------------------- ------------------------------------------------------------------ ----- ---------------------------------
  Normal                                             \< 120                                                             AND   \< 80
  Pre-hypertension                                   120--139                                                           OR    80--89
  Stage 1                                            140--159                                                           OR    90--99
  Stage 2                                            ≥ 160                                                              OR    ≥ 100

*Source*: Hypertension: The Silent Killer: Updated JNC-8 Guideline Recommendations. Alabama Pharmacy Association, Montgomery, AL, USA; 2015.^[@CIT0017]^

, Classification as per JNC8 guidelines;

, BP should be categorised according to the highest level of BP whether systolic or diastolic.

###### 

Classification of body mass index.

  Classification[†](#TFN0004){ref-type="table-fn"}   BMI[‡](#TFN0005){ref-type="table-fn"} kg/m^2^
  -------------------------------------------------- -----------------------------------------------
  Underweight                                        \< 18.50
  Normal range                                       18.50--24.99
  Overweight                                         ≥ 25.00
  Obese                                              ≥ 30.00

BMI, body mass index.

, Classification as per WHO guidelines;

, BMI = weight (kilograms)/height (metres)^2^.

Statistical analysis {#s20007}
--------------------

IBM SPSS version 24 and Stata version 13 were used for data analysis. To assess the effect of time on ordinal outcomes, the outcomes were first categorised into binary variables indicating the presence or absence of a condition. eGFR categories were collapsed into normal (eGFR ≥ 60 mL/min/1.73 m^2^) versus renal impairment (moderate to kidney failure, eGFR \< 60 mL/min/1.73 m^2^). Blood pressure categories were dichotomised to normal versus HPT -- the latter included pre-hypertension. Generalised linear models for binary data were used to model the probability of renal impairment over the five time periods, controlling for repeated measures within participants over time. Risk ratios and 95% confidence intervals (CI) were reported for each time point versus baseline. A *p-*value of \< 0.05 represented statistical significance.

### Ethical consideration {#s30008}

Ethical approval was obtained from the KwaZulu-Natal Department of Health and from the University of KwaZulu-Natal (UKZN) Biomedical Research and Ethics Council (BREC) Ethics Committee. Full ethical approval was obtained from the BREC, and permission to conduct the research was granted by King Edward VIII Hospital management. All data generated or analysed during this study are included in this published article and its supplementary information files.

Results {#s0009}
=======

Demographics {#s20010}
------------

The baseline characteristics of the 350 patients included in the analysis are illustrated in [Table 4](#T0004){ref-type="table"}. Their mean age was 36.9 years, with a standard deviation of 9.7 years. The range was from 18 to 72 years, with a median age of 36 years. The cohort was 64% female, and 99% were Black. Of the women, 16% were pregnant at baseline. Also at baseline, 10 patients had HPT, six had diabetes, 14 had a combination of HPT and diabetes mellitus and 61 were co-infected with TB. At baseline, 157 patients had a high BMI, with 25.4% being categorised as overweight and 19.4% as obese ([Figure 1](#F0001){ref-type="fig"}). Because of a lack of documentation of either the weight or height or both, 20 patients did not have their BMI documented at baseline. The mean CD4 count at baseline was 177 cells/μL, with a standard deviation of 161.9 cells/μL. The majority of the patients (59.3%) were normotensive, while 24.1% were classified as pre-HPT, 9.9% as Stage 1 HPT and 6.7% as Stage 2 HPT ([Figure 2](#F0002){ref-type="fig"}).

![Body mass index categories of 350 patients at baseline.](HIVMED-19-770-g001){#F0001}

![Hypertension categories of 350 patients at baseline.](HIVMED-19-770-g002){#F0002}

###### 

Baseline demographics of the 350 patients included in the analyses.

  Variable                    Category   *n*    \%           95% CI
  --------------------------- ---------- ------ ------------ -------------
  Gender                      Female     224    64           0.59--0.69
  Male                        126        36     0.31--0.41   
  Race                        Black      348    99.4         0.98--1.00
  Indian                      0          0      0.0          
  White                       0          0      0.0          
  Mixed race                  2          0.6    0.00--0.02   
  HPT                         No         340    97.1         0.95--0.98
  Yes                         10         2.9    0.02--0.05   
  Diabetes mellitus           No         344    98.3         0.96--0.99
  Yes                         6          1.7    0.01--0.04   
  HPT and diabetes mellitus   Yes        14     0.6          0.001--0.02
  TB                          No         288    82.5         0.78--0.86
  Yes                         61         17.5   0.14--0.22   
  Pregnant (women)            No         188    83.9         0.86--0.93
  Yes                         36         16.1   0.07--0.14   

CI, confidence intervals; HPT, hypertension; TB, tuberculosis.

Baseline renal function {#s20011}
-----------------------

At baseline, the majority of the patients (90.4%) had a normal renal function (95% CI: 86% -- 93%), 7.0% (CI: 5% -- 10%) had moderate renal impairment, 1.3% (CI: 0% -- 3%) had severe renal impairment and 1.3% (CI: 0% -- 3%) had kidney failure ([Table 5](#T0005){ref-type="table"}). The eGFR for 49 patients was not documented at baseline. Relative to baseline, the risk of developing renal failure decreased at the subsequent time points ([Appendix 1](#app001){ref-type="app"}). At six months, the risk of developing renal failure was 82% (CI: 5% -- 72%) lower than baseline, at 12 months it was 56% (CI: 22% -- 87%) lower, at 18 months it was 72% (CI: 10% -- 77%) lower and at 24 months the risk was 49% (CI: 29% -- 91%) lower than baseline.

###### 

Categories of renal impairment from baseline to 24 months on antiretroviral treatment.

  eGFR categories (eGFR mL/min/1.73 m^2^)   Baseline   6 months   12 months    18 months   24 months                                                                                                
  ----------------------------------------- ---------- ---------- ------------ ----------- ----------- ------------ --------- ------- ------------ --------- ------- ------------ --------- ------- ------------
  Normal (eGFR \> 60)                       272        90.4       0.86--0.93   112         98.2        0.93--1.00   181       95.8    0.92--0.98   143       97.3    0.93--0.99   212       95.1    0.91--0.97
  Moderate RI (eGFR 30--59)                 21         7.0        0.05--0.10   1           0.9         0.00--0.06   6         3.2     0.01--0.07   2         1.4     0.00--0.05   9         4.0     0.02--0.08
  Severe RI (eGFR 15--29)                   4          1.3        0.00--0.03   0           0.0         0            1         0.5     0.00--0.04   0         0.0     0            1         0.4     0.00--0.03
  Kidney failure (eGFR \< 15)               4          1.3        0.00--0.03   1           0.9         0.00--0.06   1         0.5     0.00--0.04   2         1.4     0.00--0.05   1         0.4     0.00--0.03
                                                                                                                                                                                                    
  **Total**                                 **301**    **-**      **-**        **114**     **-**       **-**        **189**   **-**   **-**        **147**   **-**   **-**        **223**   **-**   **-**

eGFR, estimated glomerular filtration rate; CI, confidence interval, RI, renal impairment

[Appendix 2](#app002){ref-type="app"} demonstrates the characteristics of the 29 patients with baseline renal impairment and depicts the trend of the eGFR over various time points. Of those patients with abnormal renal impairment at baseline, females predominated with renal impairment at 79%. Twenty-four per cent were co-infected with TB, while one patient had HPT. The average age of the 29 patients was 45 years. The median CD4 at baseline of these 29 patients was 147 cells/μL. Seven patients of the 29 patients (24%) with baseline renal impairment had persistent renal impairment at 24 months. Eight of the 29 patients did not have an eGFR done at 24 months. One patient was lost to follow-up at 24 months. The eGFR of 13 patients (44.8%) normalised at 24 months.

In 2010, fixed-dose combinations were unavailable in the public sector; therefore, patients were initiated on individual antiretroviral agents. The vast majority of patients were initiated on TDF (90.6%), in combination with lamivudine (3TC) (100%) and either efavirenz (EFV) (56.6%) or nevirapine (NVP) (43.4%). Twenty-three of the 29 patients with baseline renal impairment (eGFR \< 60 mL/min/1.73 m^2^) were commenced on a TDF-based regimen. Of the 10 patients with a baseline eGFR \< 50 mL/min/1.73 m^2^ who were commenced on TDF, 7 had a normalisation of eGFR by 24 months, while three experienced deterioration in renal function. Two of the patients had TDF discontinued at 18 months and replaced with abacavir (ABC). The remaining patients with renal impairment were either initiated on ABC (three patients), zidovudine (AZT) (two patients) or stavudine (d4T) (one patient). Fourteen of the 36 pregnant women were initiated on AZT, while the remaining 22 were initiated on TDF. The remaining patients were initiated on either d4T, AZT or ABC by the attending clinician as first-line treatment with no reason specified. [Figure 3](#F0003){ref-type="fig"} demonstrates this distribution of ART at baseline.

![Distribution of antiretroviral treatment at treatment initiation.](HIVMED-19-770-g003){#F0003}

Risk factors associated with abnormal renal function {#s20012}
----------------------------------------------------

The factors tested for association with abnormal renal function were age group, time, BMI and HPT. The factors which remained significant in the model are shown in [Appendix 3](#app003){ref-type="app"}. Compared with those aged under 30 years, there was no significant difference in renal impairment in those aged 30--49 years, *p* = 0.128 (CI: 2.51--1.52), while those aged ≥ 50 years were 6.8 (CI: 1.90--24.54) times more likely to develop renal impairment, *p* = 0.003. Time still remained a significant predictor. As time increased, the risk of abnormal renal function decreased. As BMI increased by one unit, the risk of renal impairment increased by 1.06 (CI: 1.03--1.10) times. A CD4 threshold of \< 200 cells/μL had no significance to the association of impaired renal function, *p* = 0.378. The association of HPT with abnormal renal function was found to be insignificant over time, *p* = 0.194. Patients with HPT and aged ≥ 40 years in comparison with those with HPT and aged \< 40 years did not show any significant risk for renal impairment, *p* = 0.226. Similarly, patients with HPT and a CD4 \< 200 cells/μL did not have a significant risk for renal impairment compared with those patients with HPT and a CD4 ≥ 200 cells/μL, *p* = 0.384. A total of 21 patients (6%) were lost to follow-up over the two years, and 94% were retained in care.

Urine dipstick analysis {#s20013}
-----------------------

Only five patients in the entire cohort had urine dipsticks performed at various time points (three at baseline, one at six months and one at 12 months). The test strip was positive for proteinuria in four of the five patients (80%), and three of these four patients (75%) with proteinuria were on a TDF-based regimen with a normal eGFR. The remaining patient had renal impairment and was on an ABC regimen.

Discussion {#s0014}
==========

We aimed to determine the risk factors and co-morbidities associated with changes in renal function in an adult cohort with HIV in South Africa. The cohort was mainly female and a large proportion of patients were either pregnant or co-infected with TB. The prevalence of renal impairment at baseline was found to be relatively low. Females predominated with baseline renal impairment and the majority of the patients were co-infected with TB. Of those patients with baseline renal impairment, the majority had a normalisation of their eGFR by 24 months. The risk of developing renal impairment decreased over the two-year period while patients were on ART. Risk factors found to be significant for renal impairment were older age, *p* = 0.003, and an increase in BMI, *p* \< 0.001. In this cohort, HPT did not impact renal impairment significantly, *p* = 0.194, nor did a CD4 \< 200 cells/μL, *p* = 0.378. Tenofovir disoproxil fumarate was the ART of choice for ART initiation along with 3TC and either NVP or EFV in keeping with South African National ART guidelines.^[@CIT0013]^ Surprisingly, one-third of the patients with baseline renal impairment were initiated on a TDF-based regimen in contravention of the standard ART guidelines. These guidelines state that TDF should not be initiated in patients with an eGFR of \< 50 mL/min/1.73 m^2^. This probably reflects the practice in clinics that may be understaffed where there may be a tendency for errors to occur.

Similar studies conducted in South Africa showed a low prevalence of baseline renal impairment in an HIV-infected cohort^[@CIT0012],[@CIT0019],[@CIT0020]^ and some showed an improvement in eGFR after starting ART.^[@CIT0019],[@CIT0021],[@CIT0022]^ Similar findings were noted in an African study by Stohr et al.^[@CIT0023]^ carried out in Mozambique and Zimbabwe. As HIV has been shown to have a direct renal pathogenic role,^[@CIT0024],[@CIT0025]^ we can deduce that treating the disease with ART diminishes the renal pathogenic effect. However, there is a lack of information on the long-term outcomes of renal disease in HIV-infected patients. Not all our patients experienced a resolution in their renal function as described earlier. Our cohort comprised mainly Black patients and therefore we were unable to compare the renal function of different ethnicities. Consensus regarding gender as a risk factor for renal dysfunction could not be arrived at, as some studies found women to be at greater risk,^[@CIT0019],[@CIT0026]^ while others found men to be at greater risk.^[@CIT0020]^ Older age has been documented in numerous studies including ours as a risk factor for renal impairment.^[@CIT0019],[@CIT0020],[@CIT0027]^ A low CD4 count, high viral load and low haemoglobin are other variables found to be associated with a lower eGFR.^[@CIT0012],[@CIT0019],[@CIT0020],[@CIT0027]^ In our study, despite having a mean CD4 of 177 cells/μL, a CD4 threshold of \< 200 cells/μL was insignificant as a risk factor for renal impairment. Majority of the cohort had a baseline CD4 \< 200 cells/μL in keeping with the National ART guidelines at the time (CD4 \< 200 qualified for ART initiation).^[@CIT0013]^ We did not assess a high viral load and low haemoglobin as variables in our study.

A high BMI has been documented in international literature as a modest risk factor for renal impairment over time.^[@CIT0027]^ To the best of our knowledge, this is the first South African study to demonstrate BMI as a risk factor associated with changes in renal function in an HIV-infected cohort. This is a significant finding as a high BMI is also a risk factor for other chronic diseases such as HPT, diabetes and cardiovascular disease,^[@CIT0028],[@CIT0029]^ which in turn are risk factors for CKD.^[@CIT0006]^Although we did not find a significant link between HPT and renal impairment, this has been observed in other studies.^[@CIT0026],[@CIT0027]^ A possible explanation for our findings could be the duration for which we collected data (two years) and ethnicity (our cohort mainly comprised Black patients), while in the other studies the duration was 96 weeks and 31 months, respectively, in predominantly White cohorts.^[@CIT0026],[@CIT0027]^

Several studies have described TDF-associated nephrotoxicity as a pattern of renal injury involving the proximal renal tubule sometimes with Fanconi syndrome occurring together with decreased renal function.^[@CIT0007],[@CIT0030]^ They recommend monitoring of renal function to prevent these outcomes.^[@CIT0010],[@CIT0030],[@CIT0031]^ The South African ART guidelines recommend monitoring of renal function with urine dipsticks, a serum creatinine and eGFR levels at baseline, six months, 12 months and annually thereafter for patients on TDF.^[@CIT0013],[@CIT0032]^ The rate of adherence to these guidelines is not known. In our study, we found missing serum creatinine and eGFR levels at six months, 12 months and 24 months. A possible explanation for this is that clinicians were attending to large clinic numbers with a poorly kept paper filing system, wherein these routine checks were missed. In addition, clinicians were missing the 12-month serum testing because they calculated the timing of this test as one year from the six-month blood test, which resulted in the test being taken at 18 months. Of those patients initiated on TDF with an eGFR \< 50 mL/min/1.73 m^2^, only a few patients had deterioration in renal function, resulting in the discontinuation of TDF. Most likely this is because the majority had a reversible cause for the renal impairment, for example, dehydration rather than actual renal disease.

Urine analysis is important to detect proximal renal tubular damage in patients on TDF as well as undiagnosed HIV-associated nephropathy (HIVAN), yet they were rarely performed in our clinic setting, again, possibly because of large volumes of clinic patients combined with staff shortages and limited ablution facilities. Fabian et al.^[@CIT0033]^ showed that urinary abnormalities were common in HIV-infected, ART-naïve outpatients and recommended that routine urinary screening of all new patients at ART clinics should be practiced. However, urine dipstick usage as a solitary screening tool is a topic with much debate, as research both locally and internationally suggests their poor validity in detecting proteinuria.^[@CIT0020],[@CIT0034]^

A study conducted in South Africa by Han et al.^[@CIT0035]^ showed that microalbuminuria alone could be an early marker for HIVAN. HIV-associated nephropathy is the most common histology seen on renal biopsy in South African patients.^[@CIT0021],[@CIT0022]^ It is commonly found in Black patients who seem to have a genetic predisposition for the disease^[@CIT0036]^ and Kasembeli et al.^[@CIT0037]^ documented this finding in a South African cohort. Therefore, by deferring urine analysis, we may be missing an opportunity to detect early HIVAN in our predominantly Black high-risk cohort. The best method for urine screening is not known.^[@CIT0006]^ Relying solely on serum creatinine levels and eGFR is inappropriate for this group of patients as HIVAN can occur with a normal renal function.^[@CIT0035]^

It is important to highlight that when boosted with ritonavir or cobicistat, the renal toxicity profile of tenofovir tends to be worse.^[@CIT0030],[@CIT0038]^ In this study, the majority of patients were treated with TDF, 3TC and either EFV or NVP, which tends to have a more favourable renal toxicity profile.^[@CIT0030],[@CIT0038]^

A strength of this study we feel is that we had a good sample size of 350 and a good representation of the profile of patients who are currently attending ART clinics across South Africa. The main limitation of the study would be that of missing data, for example, the weight, height, BP and baseline serum creatinine were not documented in some patients. Lastly, we cannot comment on the diagnosis of those with persistent renal impairment at 24 months as renal biopsies were not done.

Conclusion {#s0015}
==========

This study shows a low prevalence of baseline renal impairment among HIV-infected, ART-naïve outpatients and an improvement in renal function after the commencement of ART. This highlights the possibility of HIV being the likely cause of the renal impairment at baseline. Caution should be exercised when excluding TDF as an option at initiation owing to renal impairment, as most patients have a reversible cause for the renal dysfunction which can be corrected before ART initiation. Ultimately, TDF as part of a fixed-dose combination is a once daily dose which greatly improves adherence. Long-term outcomes of patients with HIV-related renal disease are not known. Body mass index has been associated with the development of renal impairment in an HIV-infected cohort. With the recently introduced universal access to ART in South Africa, we anticipate the affliction of chronic diseases and their complications including renal disease to increase. Therefore, prospective studies targeting patients with HIV-related renal disease are needed in South Africa. Research on the most cost-effective and accurate urine diagnostics is also needed to detect early renal disease. Urine microalbumin screening is not routinely practiced at ART clinics despite being found to be an early marker for HIVAN.^[@CIT0035]^ We need to improve and reinforce optimal primary care in our clinics, including regular BP monitoring, anthropometry and urine analysis. Lastly, we need to explore the influence of a high BMI in our HIV-infected patients and its link to CKD and other chronic diseases in order to promote a healthy lifestyle and dietician services as part of a holistic management of our patients (an area often neglected in clinical practice).
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Risk of developing renal impairment over time {#s0018}
=============================================

Generalised linear models No. of obs = 973

Optimization : MQL Fisher scoring Residual df = 968

(IRLS EIM) Scale parameter = 1

Deviance = 401.4853798 (1/df) Deviance = 0.4147576

Pearson = 972.9991345 (1/df) Pearson = 1.005164

Variance function: V(u) = u\*(1-u/1) \[Binomial\]

Link function : g(u) = ln(u) \[Log\]

BIC = -6258.726

(Std. Err. adjusted for 348 clusters in STUDYNO.)

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

 \| Semirobust

 GFR_binary \| Risk Ratio Std. Err. z P\> \|z\| \[95% Conf. Interval\]

\-\-\-\-\-\-\-\-\-\-\-\--+\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

time \|

6 months \| 0.1820932 0.1277103 -2.43 0.015 0.0460582 0.7199133

12 months \| 0.4393359 0.1536724 -2.35 0.019 0.2213403 0.8720329

18 months \| 0.2824302 0.1451236 -2.46 0.014 0.1031646 0.7731993

24 months \| 0.5142902 0.1508526 -2.27 0.023 0.2894223 0.9138699

\|

\_cons \| 0.0963455 0.0170317 -13.24 0.000 0.0681331 0.1362401

 {#s0019}

###### 

Follow-up of estimated glomerular filtration rate of the 29 patients with baseline renal impairment.

  ----------------------------------------------------------------------------------------------
  Patient       Variable    Baseline    6 months      12 months     18 months        24 months
  ------------- ----------- ----------- ------------- ------------- ---------------- -----------
  49/11\        **eGFR**\   54.79\      Nd\           \> 60\        Nd\              Nd\
  72 years      **CD4**     159         Nd            75.04\        Nd               182
                                                      178                            

  Female\       **ART**     TDF,3TC,\                                                
  BMI 27.1                  EFV                                                      

  205/11\       **eGFR**\   56.81\      \> 60\        \> 60\        \> 60\           \> 60\
  53 years      **CD4**     147         78.51\        69.05\        60.68\           60.68\
                                        213           259           312              356

  Female\       **ART**     TDF,3TC,\                                                
  BMI 28.7                  EFV                                                      

  568/10\       **eGFR**\   49.00\      Nd\           Nd\           Nd\              \> 60\
  51 years      **CD4**     2.00        Nd            Nd            Nd               86.41\
                                                                                     233

  Female\       **ART**     TDF,3TC,\                                                
  BMI nd                    EFV                                                      

  275/11\       **eGFR**\   50.46\      Nd\           Nd\           \> 60\           Nd\
  32 years      **CD4**     109         Nd            Nd            124.02\          Nd
                                                                    345              

  Female\       **ART**     TDF,3TC,\                                                
  BMI 28.1                  EFV                                                      

  371/11\       **eGFR**\   59.42\      Nd\           \> 60\        \> 60\           Nd\
  36 years      **CD4**     17          Nd            105.45\       108.88\          Nd
                                                      41            31               

  Male, TB\     **ART**     TDF,3TC,\                                                
  BMI nd                    EFV                                                      

  567/11\       **eGFR**\   46.13\      Nd\           Nd\           \> 60\           40.61\
  59 years      **CD4**     143         Nd            Nd            63.40\           161
                                                                    146              

  Male\         **ART**     TDF,3TC,\                                                
  BMI 21.3                  EFV                                                      

  578/11\       **eGFR**\   58.00\      Nd\           47.40\        Nd\              44.95\
  51 years      **CD4**     147         Nd            416           Nd               539

  Female, TB\   **ART**     TDF,3TC,\                                                
  34.60                     EFV                                                      

  587/11\       **eGFR**\   38.45\      Nd\           \> 60\        Nd\              \> 60\
  56 years      **CD4**     227         Nd            78.97\        Nd               72.68\
                                                      363                            436

  Female\       **ART**     TDF,3TC,\                                                
  BMI 46.5                  EFV                                                      

  788/11\       **eGFR**\   51.65\      Nd\           Nd\           \> 60\           Nd\
  40 years      **CD4**     236         Nd            Nd            154.48\          Nd
                                                                    50               

  Male\         **ART**     TDF,3TC,\                                                
  BMI 27                    EFV                                                      

  1033/11\      **eGFR**\   47.95\      Nd\           \> 60\        Nd\              Nd\
  60 years      **CD4**     324         Nd            90.18\        Nd               Nd
                                                      692                            

  Female\       **ART**     TDF,3TC,\                                                
  BMI 37.8                  EFV                                                      

  1111/11\      **eGFR**\   52.59\      \> 60\        \> 60\        \> 60\           \> 60\
  36 years\     **CD4**     277         86.38\        82.12\        70.40\           68.42\
  Female                                634           424           413              447

  BMI 26.4      **ART**     TDF,3TC,\   TDF,3TC,EFV                                  
                            NVP                                                      

  1145/11\      **eGFR**\   57.81\      Nd\           \> 60\        \> 60\           \> 60\
  50 years      **CD4**     365         Nd            63.45\        62.11\           72.79\
                                                      438           518              516

  Male\         **ART**     TDF,3TC,\                                                
  BMI 20.7                  EFV                                                      

  819/10\       **eGFR**\   3.68\       4.01\         Nd\           LTFU\            LTFU\
  33 years      **CD4**     13          Nd            Nd            LTFU             LTFU

  Male, HPT\    **ART**     ABC,3TC,\                                                
  BMI 22.5                  EFV                                                      

  51/12\        **eGFR**\   20.63\      59.23\        11.88\        34.26\           34.83\
  46 years      **CD4**     238         431           362           187              370

  Female\       **ART**     TDF,3TC,\                               ABC,3TC,EFV      
  BMI 46.1                  EFV                                                      

  150/12\       **eGFR**\   53.98\      Nd\           \> 60\        \> 60\           Nd\
  42 years      **CD4**     16          Nd            73.50\        79.59\           Nd
                                                      49            78               

  Female\       **ART**     TDF,3TC,\                               AZT,3TC,Aluvia   
  BMI 27.0                  NVP                                                      

  341/12\       **eGFR**\   14.17\      Nd\           Nd\           LTFU\            15.78\
  51 years      **CD4**     46          Nd            Nd            LTFU             227

  Male\         **ART**     AZT,3TC,\   ABC,3TC,EFV                                  
  BMI 32.3                  EFV                                                      

  346/12\       **eGFR**\   25.33\      Nd\           54.25\        Nd\              43,82\
  49 years      **CD4**     128         Nd            287           Nd               331

  Male, TB\     **ART**     ABC,3TC,\                                                
  BMI 25.1                  EFV                                                      

  416/12\       **eGFR**\   51.18\      Nd\           \> 60\        Nd\              \> 60\
  46 years      **CD4**     150         Nd            71.06\        Nd               80.80\
                                                      418                            393

  Female\       **ART**     TDF,3TC,\                                                FDC
  BMI 45.6                  EFV                                                      

  475/12\       **eGFR**\   37.98\      Nd\           \> 60\        Nd\              \> 60\
  30 years      **CD4**     20          Nd            83.84\        Nd               117.48\
                                                      330                            410

  Female, TB\   **ART**     TDF,3TC,\                               FDC              
  BMI 14.6                  EFV                                                      

  843/12\       **eGFR**\   58.80\      Nd\           \> 60\        Nd\              58.07\
  42 years      **CD4**     284         Nd            61.12\        Nd               591
                                                      475                            

  Female\       **ART**     TDF,3TC,\                 FDC                            
  BMI 38.1                  EFV                                                      

  431/12\       **eGFR**\   19.82\      \> 60\        Nd\           \> 60\           \> 60\
  69 years      **CD4**     139         77.02\        Nd            71.96\           73.17\
                                        328                         519              700

  Female, TB\   **ART**     ABC,3TC,\                                                
  BMI 52.8                  EFV                                                      

  476/12\       **eGFR**\   14.49\      Nd\           \> 60\        Nd\              \> 60\
  30 years      **CD4**     45          Nd            83.84\        Nd               101.81\
                                                      330                            410

  Female\       **ART**     TDF,3TC,\                                                
  BMI 14.6                  EFV                                                      

  600/12\       **eGFR**\   49.38\      Nd\           \> 60\        Nd\              \> 60\
  44 years      **CD4**     299         299           106.38\       Nd               85.89\
                                                      527                            637

  Female\       **ART**     TDF,3TC,\                                                FDC
  BMI 42.5                  EFV                                                      

  1039/10\      **eGFR**\   39.70\      Nd\           Nd\           \> 60\           \> 60\
  40 years      **CD4**     193         Nd            Nd            69.91\           76.59\
                                                                    600              566

  Female\       **ART**     AZT,3TC,\                                                
  BMI 24.8                  NVP                                                      

  1266/10\      **eGFR**\   24.22\      Nd\           24.82\        Nd\              Nd\
  49 years      **CD4**     218         287           367           Nd               Nd

  Female, TB\   **ART**     TDF,3TC,\                               ABC,3TC,EFV      
  BMI 37.4                  EFV                                                      

  1273/10\      **eGFR**\   51.55\      LTFU\         LTFU\         LTFU\            Nd\
  47 years      **CD4**     190         LTFU          LFTU          LFTU             191

  Female\       **ART**     TDF,3TC,\                                                
  BMI 47.5                  EFV                                                      

  494/10\       **eGFR**\   50.48\      Nd\           \> 60\        Nd\              \> 60\
  26 years      **CD4**     36          Nd            100.92\       Nd               77.43\
                                                      246                            198

  Female\       **ART**     D4T,3TC,\                 D4T,3TC,NVP                    
  BMI 22.8                  EFV                                                      

  1336/10\      **eGFR**\   56.99\      Nd\           \> 60\        Nd\              6.90\
  49 years      **CD4**     163         Nd            99.80\        Nd               298
                                                      222                            

  Female\       **ART**     TDF,3TC,\                                                
  BMI 21.3                  EFV                                                      

  1339/10\      **eGFR**\   46.24\      \> 60\        Nd\           Nd\              \> 60\
  25 years      **CD4**     71          110.06\       Nd            Nd               125.36\
                                        Nd                                           299

  Male, TB\     **ART**     TDF,3TC,\                                                
  BMI 19.4                  EFV                                                      
  ----------------------------------------------------------------------------------------------

Nd, not done; ART, antiretroviral treatment; TB, tuberculosis; BMI, body mass index; LTFU, lost to follow-up; FDC, fixed-dose combination.

Risk factors and co-morbidities associated with abnormal renal function {#s0020}
=======================================================================

Generalised linear models No. of obs = 972

Optimization : MQL Fisher scoring Residual df = 963

 (IRLS EIM) Scale parameter = 1

Deviance = 353.6712349 (1/df) Deviance = 0.3672598

Pearson = 991.4235583 (1/df) Pearson = 1.029516

Variance function: V(u) = u\*(1-u/1) \[Binomial\]

Link function : g(u) = ln(u) \[Log\]

 BIC = -6271.148

 (Std. Err. adjusted for 348 clusters in STUDYNO)

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

\| Semirobust

GFR_binary \| Risk Ratio Std. Err. z P\> \|z\| \[95% Conf. Interval\]

\-\-\-\-\-\-\-\-\-\-\-\--+\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

time \|

6 months \| 0.1905768 0.133623 -2.36 0.018 0.0482225 0.7531656

12 months \| 0.4020471 0.1349437 -2.71 0.007 0.2082468 0.7762033

18 months \| 0.2356236 0.1224814 -2.78 0.005 0.0850646 0.6526627

24 months \| 0.4218433 0.1191978 -3.05 0.002 0.2424556 0.7339563

\|

BMI \| 1.060231 0.0130867 4.74 0.000 1.03489 1.086194

\|

HPT \|

yes \| 1.891108 0.9282237 1.30 0.194 0.7226302 4.94899

\|

age group \|

2 \| 2.512881 1.519828 1.52 0.128 0.767985 8.22226

3 \| 6.822283 4.45519 2.94 0.003 1.896991 24.53546

\|

\_cons \| 0.0066735 0.0045581 -7.33 0.000 0.0017497 0.0254532

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

HPT categories as risk factors for abnormal renal function {#s0021}
==========================================================

Generalised linear models No. of obs = 38

Optimization : MQL Fisher scoring Residual df = 32

(IRLS EIM) Scale parameter = 1

Deviance = 213.9306761 (1/df) Deviance = 6.685334

Pearson = 500000047.4 (1/df) Pearson = 1.56e+07

Variance function: V(u) = u\*(1-u/1) \[Binomial\]

Link function : g(u) = ln(u) \[Log\]

 BIC = 97.52792

 (Std. Err. adjusted for 20 clusters in STUDYNO)

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

\| Semirobust

GFR_binary \| Risk Ratio Std. Err. z P\> \|z\| \[95% Conf. Interval\]

\-\-\-\-\-\-\-\-\-\-\-\--+\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

time \|

2 \| 1 (empty)

3 \| 1.332723 1.24129 0.31 0.758 0.2147511 8.270733

4 \| 1 (empty)

5 \| 1.432785 1.269832 0.41 0.685 0.252225 8.139054

\|

BMI \| 1.015713 0.0452353 0.35 0.726 0.9308123 1.108357

\|

age binary \|

\> =40 years \| **3.867011 4.322484 1.21 0.226 0.4324297 34.58081**

\|

CD4cat \|

\< 200 \| **0.3924614 0.421687 -0.87 0.384 0.0477759 3.223928**

\_cons \| 0.0452665 0.085947 -1.63 0.103 0.0010955 1.870445

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Note: \_cons estimates baseline risk.
